Nurix Swings To Profit In Q3 As Roche Deal Drives Revenue Surge

Nurix Therapeutics (NRIX) reported Q3 2026 net income of $549.81M, reversing a prior-year loss, driven by Roche collaboration revenue. Revenue surged to $673.06M from $7.89M YoY. Cash reserves total $1.1B. Clinical trials for bexobrutideg and NX-1607 advanced, while NX-2127 was discontinued.

Original reporting
Published Oct 13, 2026, 7:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 7:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NRIX
Neutral
high confidence
Mentioned
$NRIX
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$NRIXNeutralHigh
01

Why it matters

The earnings release provides fresh material for traders to reassess valuation and short-term price direction.

02

Market read

First report of a sizable biotech earnings beat with profit, offering actionable insight for short-term traders.

03

What to watch

Potential slowdown in partnership pipelines or regulatory hurdles for upcoming trials.

Relevance 9/10Novelty 9/10Timing: after-hours today

Background

Nurix Therapeutics reported a turnaround from loss to profit in Q3 2026, largely due to a $653M Roche license deal.

Company-level read

Ticker impact

$NRIXNeutralHigh confidence
Context

Q3 2026 earnings disclosed net income of $549.8M and $673M revenue, driven by Roche collaboration license fees.

Expected impact

likely modest downside as investors digest profit versus high valuation expectations

Evidence & confidence

Large profit surprise but share price fell 0.85% pre-close, suggesting profit taking and valuation concerns.

Market effects

Biotech sector may see renewed interest in protein degrader platforms after strong collaboration revenue.

US biotech stocks could experience short-term volatility.

Limited to investors tracking biotech earnings; no broad market impact.

Counterpoint

Despite profit, high R&D spend and reliance on collaborations could pressure future margins.

Key entities

  • Nurix Therapeutics

    Clinical-stage biopharma reporting Q3 earnings.

  • Roche

    Provided $653M in license revenue to Nurix.

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.